NASDAQ:ENTX
Entera Bio Ltd.
Entera Bio Ltd.'s revenue fell 76.8% in fiscal 2025 to $42,000 while operating margin fell to −27450.0%. Free cash flow was −$7.5M, −17802.4% of revenue, and the diluted share count rose 22.7%.Summary generated from Entera Bio Ltd.'s SEC filings. Latest annual report filed Mar 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$42,000
Revenue growth−76.8%
Revenue, 5-yr CAGR−35.1%
Gross margin0.0%
Operating margin−27450.0%
Net margin−27235.7%
ROICn/a
Return on equity−108.0%
Debt / equityn/a
Free cash flow−$7.5M
FCF margin−17802.4%
Share count change+22.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | 0 | 0 | 0 | 0 |
| Operating income | −12 | −13 | −9 | −10 | −12 |
| Net income | −12 | −13 | −9 | −10 | −11 |
| Free cash flow | −9 | −13 | −7 | −7 | −7 |
Recent filings
- 8-KDirector or officer change
Oct 6, 2026 - 8-KRegulation FD disclosure
Aug 18, 2026 - 4Insider transaction report
Aug 7, 2026 - 4Insider transaction report
Aug 7, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 7, 2026 - 8-KResults of operations and financial condition
Aug 7, 2026 - 8-KEntry into a material agreement
Jul 28, 2026 - 8-KDirector or officer change
Jul 16, 2026